Activin receptor type IIB variants and uses thereof
There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as pulmonary hypertension, fibrosis, muscle weakness and atrophy, metabolic disorders and/or cardiometabolic disease, bone damage, and/or low red blood cell levels (such as anemia).
1. A polypeptide comprising:
(a) an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant comprising the amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO: 2, wherein the ActRIIB-ECD variant comprises a substitution F58Q relative to the human wild type ActRIIB-ECD of SEQ ID NO: 2;
(b) a peptide linker comprising at least 10 amino acids; and
(c) an immunoglobulin (Ig) Fc domain monomer.
2. The polypeptide of claim 1 , wherein the ActRIIB ECD comprises the amino acid sequence that is at least 95% identical to SEQ ID NO: 9.
3. The polypeptide of claim 1 , wherein the ActRIIB-ECD variant further comprises GRGEA (SEQ ID NO: 23) at the N terminus.
4. The polypeptide of claim 1 , wherein the polypeptide comprises from N- to C-terminus: the ActRIIB-ECD-the peptide linker-the Ig Fc domain monomer.
5. The polypeptide of claim 1 , wherein the Ig Fc domain monomer is an IgG1, IgG2, IgG3 or IgG4 isotype.
6. The polypeptide of claim 5 , wherein the Ig Fc domain monomer comprises D at position 356 and L at position 358 (DL).
7. The polypeptide of claim 5 , wherein the Ig Fc domain monomer comprises E at position 356 and M at position 358 (EM).
8. The polypeptide of claim 5 , wherein the Ig Fc domain monomer further comprises lysine residue (K) at the C terminus.
9. The polypeptide of claim 1 , wherein the Ig Fc domain monomer is engineered to reduce aggregation or to modulate stability of a dimer of the polypeptide.
10. The polypeptide of claim 9 , wherein the Ig Fc domain monomer comprises the amino acid substitutions of M252Y, S254T, and T256E (YTE).
11. The polypeptide of claim 9 , wherein the Ig Fc domain monomer comprises the M252Y amino acid substitution.
12. The polypeptide of claim 1 , wherein the Ig Fc domain monomer comprises the amino acid sequence that is at least 85% identical to any one of SEQ ID NOs: 134-173 and 338.
13. The polypeptide of claim 12 , wherein the Ig Fc domain monomer is:
(a) an IgG1 isotype and comprises the amino acid sequence of SEQ ID NO: 135 or SEQ ID NO: 134; or
(b) an IgG2 isotype and comprises the amino acid sequence of SEQ ID NO: 157.
14. The polypeptide claim 1 , wherein the peptide linker is between 10 and 40 amino acids in length.
15. The polypeptide of claim 14 , wherein the peptide linker is 10 amino acids in length, 14 amino acids in length, 19 amino acids in length, or 39 amino acids in length.
16. The polypeptide of claim 14 , wherein the peptide linker comprises the amino acid sequence of any one of SEQ ID NOs: 34, 54, or 59.
17. The polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence that is at least 95% identical to any one selected from the group consisting of SEQ ID NOs: 220-223 and 253.
18. The polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 220-223 and 253.
19. The polypeptide of claim 1 , wherein the polypeptide further comprises an albumin-binding domain, a fibronectin domain, or a human serum albumin domain fused to the N- or C-terminus of the ActRIIB-ECD variant via a linker.
20. The polypeptide of claim 1 , further comprising a signal peptide of SEQ ID NO: 1 at the N-terminus of the ActRIIB-ECD variant.
21. The polypeptide of claim 1 , wherein the polypeptide binds to human activin A, activin B, growth differentiation factor (GDF)-8, GDF-11, and/or bone morphogenetic protein (BMP)-10; and has reduced binding to human BMP-9 relative to the binding of a human wild type ActRIIB-ECD to human BMP-9.
22. The polypeptide of claim 21 , wherein the polypeptide does not substantially bind to human BMP-9.
23. The polypeptide of claim 21 , wherein the polypeptide inhibits signaling of one or more of human activin A, activin B, GDF-8, GDF-11, and BMP-10.
24. The polypeptide of claim 21 , wherein the polypeptide does not inhibit human BMP-9 signaling.
25. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.
26. The pharmaceutical composition of claim 25 , wherein the composition is formulated for intravenous, subcutaneous, intraperitoneal, or intramuscular administration.
27. A transforming growth factor beta (TGFβ) superfamily ligand binding agent comprising a first polypeptide and a second polypeptide, wherein each of the first and second polypeptide comprises:
(a) an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant comprising the amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO: 2, wherein the ActRIIB-ECD variant comprises F58Q substitution relative to the human wild type ActRIIB-ECD of SEQ ID NO: 2;
(b) a peptide linker comprising at least 10 amino acids; and
(c) an immunoglobulin (Ig) Fc domain monomer,
wherein the first and second polypeptides are linked by at least one disulfide bond between the Ig Fc domain monomer of the first polypeptide and the Ig Fc domain monomer of the second polypeptide.
28. The binding agent of claim 27 , wherein each of the first polypeptide and the second polypeptide comprises the amino acid sequence that is at least 95% identical to a sequence selected from the group consisting of SEQ ID NOs: 220-223 and 253.
29. A method of treating a disease or condition associated with TGFβ-superfamily ligand signaling in a subject in need thereof, wherein the method comprises administering to said subject a therapeutically effective amount of the polypeptide of claim 1 .
30. The method of claim 29 , wherein the subject is a human.
31. The method of claim 29 , wherein the disease or condition is selected from the group consisting of pulmonary hypertension (PH), fibrosis, muscle weakness or atrophy, metabolic disorders, cardiometabolic disease, bone damage, and low red blood cell levels.
32. The method of claim 31 , wherein the PH is pulmonary arterial hypertension (PAH).
33. The method of claim 32 , wherein the PAH is idiopathic PAH; heritable PAH; or PAH associated with an infection, a congenital heart abnormality, portal hypertension, pulmonary veno-occlusive disease, pulmonary capillary hemangiomatosis, connective tissue disorder, chronic obstructive pulmonary disease, autoimmune disorder, or drug use.